Physician profile
Amy Kelley
NPI 1659321453
$8,193.50
in general payments reported to CMS, 2019-2025
56 companies · $1,147 in 2025
The $1,147 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,001 · 2020: $788 · 2021: $758 · 2022: $960 · 2023: $1,282 · 2024: $1,259 · 2025: $1,147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,688.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,687.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,290.21 | 2019-2025 | |
| Lilly USA, LLC | $778.80 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $658.26 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $488.49 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $410.67 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $339.30 | 2019-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $331.85 | 2019-2024 | Spravato, Xarelto |
| Glaxosmithkline, LLC. | $275.40 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bausch Health US, LLC | $271.84 | 2019-2025 | Aplenzin, Wellbutrin |
| Allergan, INC. | $262.31 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $260.88 | 2019-2023 | Verquvo, Segluromet, Steglatro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $254.33 | 2019-2025 | Jardiance |
| Amgen INC. | $250.02 | 2019-2025 | Repatha, Otezla, Repatha |
| Axsome Therapeutics, INC. | $203.63 | 2023-2025 | Auvelity |
| Astellas Pharma US INC | $184.25 | 2019-2025 | Veozah, Myrbetriq |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Kelley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.